Ascendis Pharma A/S granted 14,060 warrants to employees on July 14, 2026, with an exercise price of $265.57 per share. The warrants vest in stages, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting monthly over the following 36 months. Ascendis Pharma A/S is a biotechnology company focused on oncolytic and oncolytic-related therapies.

Ascendis Pharma A/S announced on June 30, 2026, new radiographic data from Week 104 of the pivotal ApproaCH Trial for once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The trial results showed continued improvements in tibial-femoral angle (TFA) and TFA Z-scores in children treated with the therapy, including a mean absolute change of -2.2 degrees in TFA in the overall population and -3.8 degrees in the subgroup with baseline TFA < 5> 5>. TransCon CNP was generally well tolerated with a ability to maintain annualized growth velocity and growth height Z-score. Ascendis Pharma A/S is a biotechnology company focused on on-demand and long-acting hormone replacement therapies.

Ascendis Pharma A/S closed a warrant exercise window on June 29, 2026, resulting in the issuance of 177,267 ordinary shares. This increased the company's nominal share capital to DKK 66,189,926. The exercises were executed at an average cash consideration of approximately USD $121.57 per share. The company subsequently amended its articles of association to reflect the capital increase. Ascendis Pharma A/S is a biotechnology company focused on developing proprietary drug delivery technologies.

On June 13, 2026, Ascendis Pharma announced Week 182 data from its Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The three-and-a-half-year study showed 86% of patients met a multi-component endpoint of normal serum calcium, no active vitamin D, and ≤600 mg/day of calcium. Key results included 100% independence from active vitamin D, 96% independence from therapeutic calcium doses, and stabilized kidney function with a mean eGFR of 80.2 mL/min/1.73 m2. Patients reported improved quality of life via HPES and SF-36 scales, while bone mineral density remained stable. The treatment was well-tolerated with no new safety signals or anti-PTH antibodies. Ascendis Pharma is a biotechnology company focused on developing transcon technology for endocrine diseases.

On June 11, 2026, Ascendis Pharma announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial for TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. Results showed 82% of patients responded to the multi-component endpoint of normal serum calcium while remaining independent of active vitamin D and taking <600 mg/day of calcium. Specifically, 96% achieved independence from active vitamin D and 95% from therapeutic calcium doses. Mean eGFR increased by 9.4 mL/min/1.73 m2 from baseline and was sustained over five years. The treatment was generally well-tolerated with no new safety signals and no drug-related discontinuations. The company operates in the biopharmaceutical industry and develops endocrine-focused therapies.

On June 9, 2026, Ascendis Pharma A/S's board of directors granted 27,030 warrants to specific employees. Each warrant allows for the subscription of one ordinary share at an exercise price of $213.23 per share. The warrants follow a vesting schedule where 25% vest on the one-year anniversary of the grant, with the remaining 75% vesting monthly over 36 months thereafter, subject to continued service and certain exit events. Following this issuance, 1,553,563 warrants remain available for future grants. The company amended its Articles of Association to facilitate this grant. Ascendis Pharma A/S is a biotechnology company focused on developing proprietary technologies for hormone therapies.